AstraZeneca’s Imfinzi is adding yet another landmark perioperative label to its belt with a new FDA approval that gives the ...

The United States has revealed price reductions for the second round of | The U.S. has revealed price reductions for the ...

Less than a week after Novartis unveiled a plan to establish a “flagship manufacturing hub” in North Carolina that would add ...

More than 30 agents conducted a surprise raid of Sanofi’s headquarters in Paris on Tuesday morning as part of a tax fraud ...

The U.K. drug marketing watchdog has ruled that a presentation calling the European Medicines Agency (EMA) “stupid” brought ...

A short film that premiered earlier this month tracks the journeys of three people who discovered a renewed commitment to ...

With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) ...

Novartis is pricing Itvisma at a wholesale acquisition cost of $2.59 million, a company spokesperson told Fierce Pharma. At ...

A new FDA approval for a first-in-class drug has vaulted Otsuka into immunoglobulin A nephropathy (IgAN), an increasingly competitive kidney disease field targeted by multiple biopharma companies.

Novo Nordisk is using its ticket for an extra-speedy regulatory review granted through the FDA’s Commissioner’s National ...

As the researchers behind Pfizer and Astellas' Padcev and Merck's Keytruda have taken victory laps on the heels of the ...

A recent survey has found that pharma marketing and promotional review professionals are skeptical of the outputs of ...